Cell-Penetrating Peptide and siRNA-Mediated Therapeutic Effects on Endometriosis and Cancer In Vitro Models
Open Access
- 5 October 2021
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (10) , 1618
Abstract
Gene therapy is a powerful tool for the development of new treatment strategies for various conditions, by aiming to transport biologically active nucleic acids into diseased cells. To achieve that goal, we used highly potential delivery vectors, cell-penetrating peptides (CPPs), as oligonucleotide carriers for the development of a therapeutic approach for endometriosis and cancer. Despite marked differences, both of these conditions still exhibit similarities, like excessive, uncoordinated, and autonomous cellular proliferation and invasion, accompanied by overlapping gene expression patterns. Thus, in the current study, we investigated the therapeutic effects of CPP and siRNA nanoparticles using in vitro models of benign endometriosis and malignant glioblastoma. We demonstrated that CPPs PepFect6 and NickFect70 are highly effective in transfecting cell lines, primary cell cultures, and three-dimensional spheroids. CPP nanoparticles are capable of inducing siRNA-specific knockdown of therapeutic genes, ribonucleotide reductase subunit M2 (RRM2), and vascular endothelial growth factor (VEGF), which results in the reduction of in vitro cellular proliferation, invasion, and migration. In addition, we proved that it is possible to achieve synergistic suppression of endometriosis cellular proliferation and invasion by combining gene therapy and hormonal treatment approaches by co-administering CPP/siRNA nanoparticles together with the endometriosis-drug danazol. We suggest a novel target, RRM2, for endometriosis therapy and as a proof-of-concept, we propose a CPP-mediated gene therapy approach for endometriosis and cancer.Keywords
Funding Information
- Eesti Teadusagentuur (IUT20-26, PRG1076)
- European Regional Development Fund (2014-2020.4.01.15-0013)
- Ettevõtluse Arendamise Sihtasutus (EU48695)
- European Commission (EU952516)
This publication has 48 references indexed in Scilit:
- Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluationBMC Biology, 2012
- Intracellular Delivery of Short Interfering RNA in Rat Organ of Corti Using a Cell-penetrating Peptide PepFect6Molecular Therapy Nucleic Acids, 2012
- Cell-Penetrating Peptides, PepFects, Show No Evidence of Toxicity and ImmunogenicityIn VitroandIn VivoBioconjugate Chemistry, 2011
- Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivoNucleic Acids Research, 2011
- Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticlesNature, 2010
- Tissue-Penetrating Delivery of Compounds and Nanoparticles into TumorsCancer Cell, 2009
- Spheroid-based drug screen: considerations and practical approachNature Protocols, 2009
- Peritoneal stromal endometriosis: a detailed morphological analysis of a large series of cases of a common and under-recognised form of endometriosisJournal of Clinical Pathology, 2009
- Cholesteryl Oligoarginine Delivering Vascular Endothelial Growth Factor siRNA Effectively Inhibits Tumor Growth in Colon AdenocarcinomaMolecular Therapy, 2006
- Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non–small cell lung cancer cellsMolecular Cancer Therapeutics, 2005